Galiximab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD80 |
| Identifiers | |
| CAS Number | 357613-77-5  |
| ATC code | none |
| UNII | S9OX9692ZB  |
| KEGG | D04295 |
| (what is this?) (verify) |
|
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009[update], it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Pages with reference errors
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
